To clarify whether serum aldolase A is a useful biomarker for renal cell carcinoma (RCC), we determined serum levels of the aldolase A isozyme by an enzyme immunoassay in patients suffering from RCC, other urological tumors, and benign urological diseases. Forty-six of 126 patients with RCC (37%) ha
Serum beta 2 microglobulin levels in patients with renal cell carcinoma
β Scribed by Selli, C. ;Cozzolino, F. ;Carini, M. ;Lenzi, R. ;Vercelli, D.
- Publisher
- Springer
- Year
- 1984
- Tongue
- English
- Weight
- 229 KB
- Volume
- 12
- Category
- Article
- ISSN
- 0300-5623
No coin nor oath required. For personal study only.
β¦ Synopsis
Serum B2m concentrations were evaluated preoperatively in 40 patients with renal cell carcinoma and normal renal function, as assessed by serum creatinine less than 1.4 mg/dl, and compared with those of 23 age-matched controls. Mean value +/- SD was 3,088 +/- 966 ng/ml for renal cancer patients, while controls had a value of 1,800 +/- 240 ng/ml. Statistical analysis, performed by Student t test, revealed a very high degree of significance (p less than 0.0005). No statistically significant differences were found between groups of patients classified according to tumor stage and cell type. Seventy percent of renal cell carcinoma cases had preoperatively elevated serum levels of B2m.
π SIMILAR VOLUMES
The levels of alpha-1 microglobulin (alpha 1m) and beta-2 microglobulin (beta 2m) in serum were estimated in 77 bone marrow transplant recipients. In comparison to pre-transplant levels, the highest levels of alpha 1m and beta 2m were found during impairment of renal function, i.e., during cyclospor